Los Angeles Capital Management
CGEM icon

Los Angeles Capital Management’s Cullinan Oncology CGEM Stock Holding History

Los Angeles Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139K Buy
7,641
+7,335
+2,397% +$109K ﹤0.01% 1263
2026
Q1 		$4.35K Sell
306
-775
-72% -$9.96K ﹤0.01% 2164
2025
Q4 		$8.17K Buy
+1,081
New +$9.75K ﹤0.01% 2145

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Los Angeles Capital Management's CGEM Position: Q2 2026 in Review

Los Angeles Capital Management increased its Cullinan Oncology (CGEM) stake by 2,397% in Q2 2026, buying an estimated $109K and bringing the position to 7,641 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #1263.

Los Angeles Capital Management first reported a position in CGEM in Q4 2025 and has held it in 3 quarters since. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Los Angeles Capital Management held 7,641 shares of Cullinan Oncology worth $139K as of Q2 2026.
  • Los Angeles Capital Management bought 7,335 Cullinan Oncology shares in Q2 2026, an estimated $109K.
  • Cullinan Oncology made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1263 holding.
  • Los Angeles Capital Management first reported a position in Cullinan Oncology in Q4 2025 and has held it in 3 quarters since.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.